These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 20027686)

  • 1. Performance value of high risk factors in colorectal cancer screening in China.
    Meng W; Cai SR; Zhou L; Dong Q; Zheng S; Zhang SZ
    World J Gastroenterol; 2009 Dec; 15(48):6111-6. PubMed ID: 20027686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy comparison among high risk factors questionnaire and Asia-Pacific colorectal screening score and their combinations with fecal immunochemical test in screening advanced colorectal tumor].
    Zhu N; Huang YQ; Song YM; Zhang SZ; Zheng S; Yuan Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jul; 25(7):612-620. PubMed ID: 35844124
    [No Abstract]   [Full Text] [Related]  

  • 3. [Evaluation of optimized sequential screening program of colorectal cancer in current China].
    Li Q; Yu L; Xue F; Ma W; Yao K
    Zhonghua Yu Fang Yi Xue Za Zhi; 2014 Nov; 48(11):995-1000. PubMed ID: 25582372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of colonoscopy-detected serrated polyps with synchronous advanced neoplasia in average-risk individuals.
    Álvarez C; Andreu M; Castells A; Quintero E; Bujanda L; Cubiella J; Salas D; Lanas Á; Carballo F; Morillas JD; Hernández C; Jover R; Sarasqueta C; Enriquéz-Navascués JM; Hernández V; Estévez P; Macenlle R; Sala T; Balaguer F; Pellisé M; Moreira L; Gil I; Peris A; González-Rubio F; Ferrández A; Poves C; Ponce M; Grau J; Serradesanferm A; Ono A; Cruzado J; Pérez-Riquelme F; Alonso-Abreu I; Carrillo-Palau M; Santander C; Díaz Tasende J; Herreros A; Cacho G; Barranco LE; Bessa X;
    Gastrointest Endosc; 2013 Aug; 78(2):333-341.e1. PubMed ID: 23623039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the performance of guaiac-based and two immunochemical fecal occult blood tests for identifying advanced colorectal neoplasia in Taiwan.
    Ou CH; Kuo FC; Hsu WH; Lu CY; Yu FJ; Kuo CH; Wang JY; Wu MT; Shiea J; Wu DC; Hu HM
    J Dig Dis; 2013 Sep; 14(9):474-83. PubMed ID: 23701988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study.
    Gimeno-García AZ; Quintero E; Nicolás-Pérez D; Hernández-Guerra M; Parra-Blanco A; Jiménez-Sosa A
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1062-7. PubMed ID: 19307978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Distribution characteristics and risk factors of colorectal adenomas].
    Zhou H; Shen Z; Zhao J; Zhou Z; Xu Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Jun; 21(6):678-684. PubMed ID: 29968244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening.
    van Rossum LG; van Rijn AF; van Oijen MG; Fockens P; Laheij RJ; Verbeek AL; Jansen JB; Dekker E
    Int J Cancer; 2009 Aug; 125(4):746-50. PubMed ID: 19408302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use.
    Rozen P; Comaneshter D; Levi Z; Hazazi R; Vilkin A; Maoz E; Birkenfeld S; Niv Y
    Cancer; 2010 May; 116(9):2115-25. PubMed ID: 20186820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The factors associated with negative colonoscopy in screening subjects with positive immunochemical stool occult blood test outcomes.
    Ting PH; Lin XH; Jiang JK; Luo JC; Chen PH; Wang YP; Hsin IF; Perng CL; Hou MC; Lee FY
    J Chin Med Assoc; 2018 Sep; 81(9):759-765. PubMed ID: 29778550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of a colonoscopic screening programme in first-degree relatives of patients with colorectal cancer.
    Puente Gutiérrez JJ; Marín Moreno MA; Domínguez Jiménez JL; Bernal Blanco E; Díaz Iglesias JM
    Colorectal Dis; 2011 Jun; 13(6):e145-53. PubMed ID: 21564467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical predictors of colorectal polyps and carcinoma in a low prevalence region: results of a colonoscopy based study.
    Bafandeh Y; Khoshbaten M; Eftekhar Sadat AT; Farhang S
    World J Gastroenterol; 2008 Mar; 14(10):1534-8. PubMed ID: 18330943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colorectal cancer screening: comparison of transferrin and immuno fecal occult blood test.
    Chen JG; Cai J; Wu HL; Xu H; Zhang YX; Chen C; Wang Q; Xu J; Yuan XL
    World J Gastroenterol; 2012 Jun; 18(21):2682-8. PubMed ID: 22690078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed.
    Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Leshno M; Niv Y
    Aliment Pharmacol Ther; 2009 Apr; 29(8):906-17. PubMed ID: 19183147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal neopterin level determination: can be a useful screening test for colorectal polyps?
    Kilciler AG; Kutluana U; Mizrak S
    Eur J Gastroenterol Hepatol; 2021 May; 33(5):655-661. PubMed ID: 33787539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.
    Lieberman DA; Weiss DG;
    N Engl J Med; 2001 Aug; 345(8):555-60. PubMed ID: 11529208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal screening using the immunochemical faecal occult blood test kit among the Malaysian cohort participants.
    Abdullah N; Abd Jalal N; Ismail N; Kamaruddin MA; Abd Mutalib NS; Alias MR; Mazlan L; Sagap I; Jamal R
    Cancer Epidemiol; 2020 Apr; 65():101656. PubMed ID: 31923638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New immunochemical fecal occult blood test with two-consecutive stool sample testing is a cost-effective approach for colon cancer screening: results of a prospective multicenter study in Chinese patients.
    Li S; Wang H; Hu J; Li N; Liu Y; Wu Z; Zheng Y; Wang H; Wu K; Ye H; Rao J
    Int J Cancer; 2006 Jun; 118(12):3078-83. PubMed ID: 16425283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.
    Battaglia P; Baritono E; Remo A; Vendraminelli R; Conti A
    Tumori; 2014; 100(2):122-7. PubMed ID: 24852854
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.